J. Goldman & CO LP Insmed Inc Call Options Transaction History

J. Goldman & CO LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$22.0 - $69.71 $1.78 Million - $5.65 Million	-81,000 Reduced 80.2%	20,000 $1.34 Million
Q1 2024 May 15, 2024	BUY	$25.72 - $29.94 $2.6 Million - $3.02 Million	101,000 New	101,000 $2.74 Million
Q4 2020 Feb 16, 2021	SELL	$31.45 - $40.54 $984,385 - $1.27 Million	-31,300 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$26.0 - $34.5 $813,800 - $1.08 Million	31,300 New	31,300 $1.01 Million
Q3 2018 Nov 14, 2018	SELL	$18.95 - $28.08 $1.71 Million - $2.53 Million	-90,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$20.0 - $29.72 $1.15 Million - $1.71 Million	57,500 Added 176.92%	90,000 $2.13 Million
Q4 2017 Feb 14, 2018	BUY	$26.43 - $31.78 $171,795 - $206,570	6,500 Added 25.0%	32,500 $1.01 Million
Q3 2017 Nov 14, 2017	BUY	$11.61 - $31.21 $301,860 - $811,460	26,000	26,000 $811,000

467

182M

2.27M

3.33M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.